Practical IT During a Crisis: The Suite Spot

On this episode of The Suite Spot, hosts Carlos Vargas, Howard Holton and Paul Lewis continue to highlight how IT teams and leaders can prepare to be agile and successful in the wake of the coronavirus crisis.

Powered by RedCircle

 

This crisis has hit IT organizations particularly hard mainly due to inexperience with disruption on this scale, at least in an economic and technological climate as advanced as our modern landscape.

The trio explored changes that have already been made in an effort to maintain productivity and efficiency under the strain of the pandemic – many of which will need to be incorporated into long-term IT strategies for both normal operation and in case of similar disruptions in the future.

The biggest, perhaps, is in finding ways to ensure the heart of any organizations – its people – are bought-into strategies and prepared adequately to stay ahead of the curve.
With the right team energy and mindset, the best practices for handling increased security challenges related to remote work, rethinking capabilities and connectivity, and more can be tackled as they come with proactive, not reactive, efforts.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More